Mechanisms underlying the tissue-specific and regulated activity of the Gnrhr promoter in mammals by Anne-Laure Schang et al.
“fendo-03-00162” — 2012/12/11 — 20:28 — page 1 — #1
REVIEW ARTICLE
published: 13 December 2012
doi: 10.3389/fendo.2012.00162
Mechanisms underlying the tissue-speciﬁc and regulated
activity of the Gnrhr promoter in mammals
Anne-Laure Schang, Bruno Quérat,Violaine Simon, Ghislaine Garrel, Christian Bleux, Raymond Counis,
Joëlle Cohen-Tannoudji and Jean-Noël Laverrière*
Physiologie de l’Axe Gonadotrope, Biologie Fonctionnelle et Adaptative, EAC CNRS 4413, Sorbonne Paris Cité, Université Paris Diderot-Paris 7, Paris, France
Edited by:
Hubert Vaudry, University of Rouen,
France
Reviewed by:
JaeYoung Seong, Korea University,
South Korea
Ursula B. Kaiser, Brigham and
Women’s Hospital, USA
*Correspondence:
Jean-Noël Laverrière, Physiologie de
l’Axe Gonadotrope, Biologie
Fonctionnelle et Adaptative, EAC
CNRS 4413, Sorbonne Paris Cité,
Université Paris Diderot-Paris 7,
Bâtiment Buffon, case courrier
7007, 4 rue MA Lagroua Weill-Hallé,
75205 Paris Cedex 13, France.
e-mail: jean-noel.laverriere@univ-paris-
diderot.fr
The GnRH receptor (GnRHR) plays a central role in the development and maintenance of
reproductive function in mammals. Following stimulation by GnRH originating from the
hypothalamus, GnRHR triggers multiple signaling events that ultimately stimulate the syn-
thesis and the periodic release of the gonadotropins, luteinizing-stimulating hormone (LH)
and follicle-stimulating hormones (FSH) which, in turn, regulate gonadal functions includ-
ing steroidogenesis and gametogenesis.The concentration of GnRHR at the cell surface is
essential for the amplitude and the speciﬁcity of gonadotrope responsiveness.The number
of GnRHR is submitted to strong regulatory control during pituitary development, estrous
cycle, pregnancy, lactation, or after gonadectomy. These modulations take place, at least
in part, at the transcriptional level. To analyze this facet of the reproductive function, the 5′
regulatory sequences of the gene encoding the GnRHR have been isolated and character-
ized through in vitro and in vivo approaches.This review summarizes results obtained with
the mouse, rat, human, and ovine promoters either by transient transfection assays or by
means of transgenic mice.
Keywords: GnRH receptor, promoter regions, transcription, gonadotrope cell lines, steroidogenic factor 1,
homeodomain proteins, transgenic mice
INTRODUCTION
Two GnRH systems (GnRH decapeptides and speciﬁc receptors)
originally existed in the common mammalian ancestor but a large
number of extant species have lost either the second type GnRH
or its receptor (Stewart et al., 2009). Humans possess GnRH-II
but lack a functional type-II receptor whereas mouse and rats
lack both of them. In this paper, we will be dealing with the
only GnRH system that has been proved to be involved in the
reproductive hormonal cascade and that was retained in either
humans or the two rodent models. The pituitary GnRH recep-
tor (GnRHR) plays a central role in mammalian reproductive
function since it establishes a unique molecular link between its
ligand, the decapeptide GnRH originating from the hypothala-
mus, and the gonadotrope cells in the anterior pituitary. The
hypothalamic GnRH is released into the portal hypophyseal vas-
culature in a periodic manner through a pulse generator that,
likely by means of both gap junctions and voltage-gated calcium
channels, coordinates the activity of individual neurons diffusely
distributed in the hypothalamus (Vazquez-Martinez et al., 2001).
Within the anterior pituitary, GnRH binds to speciﬁc high-afﬁnity
receptors present at the surface of the gonadotrope cells and
induces increase in the synthesis and pulsatile release of the
gonadotropins, luteinizing and follicle-stimulating hormones (LH
and FSH). The pituitary hormones, which are composed of a
common α- and distinct β-subunits, then enter the systemic cir-
culation and, via speciﬁc receptors, modulate gonadal functions
including gametogenesis, steroidogenesis, and ovulation. The
amplitude and frequency of GnRH pulses relayed by the GnRHR
appear critical in the development of the reproductive function,
in the onset of puberty and throughout the menstrual or estrous
cycle.
INTRACELLULAR SIGNALING AND GnRHR-MEDIATED EFFECTS
The activation of GnRHR may trigger several intracellular sig-
naling pathways in gonadotrope cells depending on the cellular
context. Twomouse gonadotrope tumor-derived cell lines express-
ing the GnRHR, αT3-1 and LβT2 cell lines, have been used as
homogenous cell models to study gonadotrope function (Win-
dle, et al., 1990; Alarid et al., 1996; Thomas et al., 1996; Turgeon
et al., 1996). In both cell lines, GnRH activates the protein kinase
C (PKC)-dependent signaling pathway through coupling to G
proteins of the Gq/G11 family (see review in Anderson, 1996).
In primary culture of rat pituitary cells under sustained GnRH
stimulation, a cAMP/PKA pathway is preferentially recruited
(Garrel et al., 2010). In the gonadotrope-derived LβT2 cell line,
sustained stimulation of GnRHR activates the cAMP signaling
pathway through PKC δ and ε (Larivière et al., 2007). Also, in
these cells, GnRHR signaling has been shown to further involve
the three mitogen-activator protein kinases (MAPK) subfami-
lies (Liu et al., 2002). In non-gonadotrope cells like insect or rat
lactosomatotrope cells stably transfected with GnRHR, the sig-
naling mechanisms may involve the PKA pathway via Gs or Gi
(Stanislaus et al., 1996; Delahaye et al., 1997; see review in Kraus
et al., 2001). GnRHR activation generates several intracellular
processes in the gonadotropes leading to enhanced transcrip-
tion of the common α and speciﬁc LH and FSHβ subunit
genes and secretion of these gonadotropins. Among these pro-
cesses have been described activation of the neuronal nitric oxide
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synthase, induction of cfos expression, increase in the early
growth response protein 1, increase in mRNA for annexin 5
and activation of translation and phosphorylation of the pitu-
itary adenylate cyclase activating polypeptide (PACAP) type 1
receptor (see review in Garrel et al., 1995, 1997, 1998; Lozach
et al., 1998; Brown and McNeilly, 1999; Sosnowski et al., 2000;
Bachir et al., 2001, 2003; Duan et al., 2002; Kawaminami et al.,
2002; Liu et al., 2002; Larivière et al., 2008). A global proﬁle
of genes regulated by GnRH in the LβT2 gonadotrope cell line
was established through microarray analysis showing that more
than 200 genes are either up- or down-regulated after GnRH
agonist treatment (Kakar et al., 2003). The amplitude of these
events is strictly dependent on the number of GnRHR molecules
at the surface of the pituitary gonadotropes that is itself depen-
dent, at least in part, on the transcriptional level of GnRHR gene
(Gnrhr).
GENE STRUCTURE AND PATHOLOGIES ASSOCIATED WITH MUTATIONS
AFFECTING THE HUMAN GENE
The cloning of its encoding cDNA, ﬁrstly in the mouse and sub-
sequently in other mammalian species, revealed that GnRHR is
325–328 amino acid long (327 in mouse and rat, 328 in human)
and conﬁrmed that this receptor belongs to the serpentine family
of transmembrane G protein-coupled receptors (review in Nor-
witz et al., 1999a and references therein). The cDNA probes have
subsequently been used to characterize the gene and its chro-
mosomal localization in various mammalian species. Gnrhr is
composed of three exons and two introns and is approximately
15–31 kb in size depending on the species (Figure 1). It is
localized to chromosome 4q21.2 in human, chromosome 4, 5,
6, or 8 in bovine, murine, ovine, and porcine species, respec-
tively (Fan et al., 1994; Kaiser et al., 1994; Morrison et al., 1994;
Kakar and Neill, 1995; Kottler et al., 1995; Leung et al., 1995;
Montgomery et al., 1995; Connor et al., 1999; Jiang et al., 2001).
Cloning of the human GNRHR cDNA has led to the identiﬁcation
of mutations in the coding sequence that are associated with
variable clinical features ranging from partial to complete hypog-
onadotropic hypogonadism (Achermann et al., 2001; de Roux and
Milgrom, 2001). Two separate groups initially reported loss-of-
function mutations in the GNRHR gene in patients with isolated
hypogonadotropic hypogonadism (de Roux et al., 1997; Layman
et al., 1998). A natural knockout of the human GNRHR resulting
from aberrant splicing that eliminates exon 2 and creates a frame
shift in the coding sequencewas reported (Silveira et al., 2002). The
woman affected by this homozygous mutation presented with pri-
mary amenorrhea, absence of gonadotropin pulsatility and did
not respond to exogenous pulsatile or acute GnRH administra-
tion. To date, at least 20 additional mutations in GNRHR have
been identiﬁed in patients with sporadic and familial isolated
hypogonadotropic hypogonadism (Chevrier et al., 2011; Noel and
Kaiser, 2011). These data again lay emphasis on the predominant
role of GNRHR in the development of reproductive function in
humans.
TISSUE- AND CELL-SPECIFIC EXPRESSION OF THE GnRHR
The isolation of the cDNA also provided the basic tools for ini-
tiating studies on the regulation of Gnrhr expression by in situ
hybridization, northern blotting, and semi quantitative RT-PCR.
The presence of transcripts for the GnRHRs have notably been
observed in brain regions previously shown to bind radiolabeled
GnRH, thus conﬁrming that Gnrhr is expressed in non-pituitary
tissues, notably in the hippocampus and hypothalamus (see review
in Jennes et al., 1997). Gnrhr is also expressed in granulosa cells
of atretic follicles in the ovary, in Leydig cells in the testis, in
prostate, breast, and placenta (Stojilkovic et al., 1994). In the pitu-
itary, the expression of Gnrhr is restricted to the gonadotrope cells
despite the common origin of the six different secreting cell types
that composed the anterior pituitary (Scully and Rosenfeld, 2002).
Exon I Exon II Exon III
3'UTR (2 kb)ATG +1 +522 +523 +741 +742 +987
Intron  4.2 kb Intron 5.0 kbHuman gene
mRNA
Rat gene
Mouse gene
Intron 26.0 kb Intron 2.8 kb
Intron 11.8 kb Intron 2.9 kb
FIGURE 1 | Structure of the GnRH receptor gene.The GnRH receptor gene
is 15–31 kb in size depending on the species. This is primarily due to
differences in intron sizes which are indicated at the top of the ﬁgure for
mouse, rat, and human species. The coding sequence is boxed with the
trans-membrane domains speciﬁed in black. The 5′ and 3′ untranslated
regions (UTR) are designated by thick black lines whereas the two introns are
speciﬁed by thick gray lines. The mature mRNA resulting from usual
intron splicing is illustrated below the gene. Sizes of translated sequences
included in the human mature transcript are indicated (987 bp corresponding
to 328 codons excluding the stop codon). Rat and mouse translated
sequences are 327 amino acids long, the exon II being three bases shorter
(+523/+738).
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These diverse and discrete sites of expression raise the question of
the mechanisms that determine the tissue-speciﬁc expression of
Gnrhr. In addition, Gnrhr is regulated by extracellular signals, the
ﬁrst of them being GnRH itself. Endocrine factors such as estra-
diol (E2), progesterone, or testosterone also regulate the levels of
Gnrhr mRNA (Stojilkovic et al., 1994). Altogether, these data led
several groups to investigate the mechanisms that underlie the
tissue-speciﬁc expression and regulation of Gnrhr (see review in
Hapgood et al., 2005).
To this aim, the 5′ regulatory sequences of the rat, mouse,
and human receptor genes have been isolated and characterized
essentially by transient transfection assays and gel-shift analy-
ses. A limited number of studies have also been conducted in
vivo through the elaboration of transgenic mouse lines harbor-
ing a reporter gene under the control of the mouse, rat, or ovine
promoter. This review focuses on the present state of knowledge
related to the cell-speciﬁc and regulated activity of the promoter
of the Gnrhr in vitro and in vivo.
IN VITRO ANALYSIS OF THE MOUSE, RAT, AND HUMAN
PROMOTERS
The tissue-speciﬁc and regulated activity of the rodent promot-
ers have been evaluated using three main cellular models; the
αT3-1 and LβT2 mouse gonadotrope-derived cell lines that are
commonly used for studying the expression of marker genes
of the gonadotrope lineage (Windle, et al., 1990; Alarid et al.,
1996; Thomas et al., 1996; Turgeon et al., 1996) and a rat cell
line of lactosomatotrope origin, the GGH(3) cells which were
obtained by stable transfection with GnRHR of the tumor-derived
GH3 cell line (Janovick et al., 1994; Kaiser et al., 1994; Stanis-
laus et al., 1994). αT3-1 cells express early marker genes of the
developing gonadotrope in mouse, the gene encoding the com-
monα-subunit of the three pituitary glycoprotein hormones (Cga)
detected at embryonic day 11.5 (E11.5), Gnrhr detected at E13.5
and steroidogenic factor 1 (Sf1, formally nuclear receptor sub-
family 5, member 1, NR5A1) detected at E14.5. The LβT2 cell
line further expresses later marker genes, namely those encod-
ing the β-subunits of LH (Lhb), from E16.5 onward, and FSH
(Fshb), from E17.5. These data together with the way by which
these cell lines were generated – by targeted oncogenesis using
the promoter of Cga and Lhb, respectively – strongly suggest
that the αT3-1 cell line may be representative of the gonadotrope
lineage at early developmental stages, between E14 and E16.5.
In contrast, the LβT2 cell line would be derived from cells at
later stage, beyond E17.5 (Ingraham et al., 1994; Japón et al.,
1994; Granger et al., 2004). It has to be emphasized that GGH3
cells express different tissue-speciﬁc transcription factors such
as pituitary-speciﬁc transcription factor 1 (PIT1 formally POU
domain class 1 transcription factor 1, POU1F1) that directs the
expression of Prl, Gh, and Tshb (Bodner et al., 1988; Ingraham
et al., 1988; Li et al., 1990; Ngô et al., 1995). Also, gonadotrope
and lactosomatotrope cells likely express ubiquitous transcrip-
tion factors at different levels. Moreover, as already mentioned
above, the GnRHR seems to be coupled to slightly different sig-
nal transduction pathways in these cell lines. Consequently, the
results obtained with these cellular models may reﬂect these major
differences.
ELEMENTS INVOLVED IN THE GONADOTROPE-SPECIFIC ACTIVITY OF
THE MOUSE AND RAT Gnrhr
The mouse promoter (Figure 2A)
SF1, AP1, and GRAS elements. The 1.2 kb promoter of the
mouse Gnrhr was the ﬁrst to be isolated and characterized in
1994 by Albarracin et al. (1994) Shortly after, a 1.9 kb mouse pro-
moter was further isolated and functionally characterized (Clay
et al., 1995). Both studies allowed identiﬁcation of multiple tran-
scription start sites within the ﬁrst 100 bp immediately upstream
from the ATG codon, the major one being located 62 nucleotides
from the translation start codon. This transcription start site was
referred to as position +1 in papers dealing with the mouse pro-
moter. However, owing to the presence of multiple transcription
start sites in GnRHR promoters and in order to facilitate the com-
parison between promoters of different species, we chose to use
the translation start site as the position +1 in this review. Con-
sequently, numbering in this review differs by +63 nucleotides
from that currently used for the mouse promoter. This core pro-
moter domain does not exhibit any typical CAAT or TATA boxes
close to the transcription start sites. Both studies also demon-
strated that the highest levels of promoter activity after transient
transfection were obtained in mouse αT3-1 gonadotrope-derived
cells. In rat lactosomatotrope cell line (GH3) or human JEG-3
placental cells, the activity of the mouse promoter was consider-
ably weaker and represented only 17 and 5% of that observed
in αT3-1 cells, respectively. Progressively, it appeared that all
the positive regulatory elements involved in the tissue-speciﬁc
activity of the mouse promoter in gonadotrope cells were con-
ﬁned into the 500 bp proximal region (Duval et al., 1997a,b).
Three distinct motifs making up a tripartite basal enhancer are
essentially required: a SF1 (NR5A1) response element (−243 5′-
TGGCCTTCA-3′ −235), a canonical activating protein 1 (AP1)
motif (−336 5′-TGAGTCA-3′ −330), and a novel element termed
GnRHR activating sequence (GRAS; −391 5′-CTAGTCACAACA-
3′ −380; Figure 2). Mutation of all three elements fully abrogates
promoter activity. The identity of SF1 was further corroborated by
gel-shift and antibody super-shift assays. Using similar approaches,
theAP1 complex has been found to involve factors likely belonging
to the FOS and JUN families. The nature of the factors that bind
the GRAS element were also deciphered. They consist of SMAD3
(mothers against decapentaplegic homolog 3)which interactswith
SMAD4 and bind to the 5′ end of the GRAS motif, AP1 that binds
within the middle of the motif, and FOXL2, a member of the
forkhead family, that interacts with the 3′ end of the GRAS
motif. GRAS is thus a composite regulatory element whose func-
tional activity is dependent on a multi-protein complex (Ellsworth
et al., 2003a).
Homeobox transcription factors. Several homeobox factors
further participate in the combinatorial code that directs
gonadotrope-speciﬁc expression of the mouse Gnrhr promoter.
The paired-like homeodomain transcription factor 1 (PITX1)
belongs to the expanding family of bicoid-related vertebrate home-
oboxgenes. It appears very early, being involved in the speciﬁcation
of the adenohypophyseal placode and its expression in the ante-
rior pituitary persists afterward until adulthood (Drouin et al.,
1998; Schlosser, 2006). PITX1 regulates different marker genes in
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GRAS
-391/-380
Activin responsiveness
SURG II
-338/-330
Homologous GnRH up-regulation
A - Mouse promoter
TGGCCTTCATGAGTCACTAGTCACAACA TGACGTTT
Major transcription start site (-62)
+1
ATG
D-LIRE
-994/-961
-363/-342
PARE I 
-260/-246
PARE II
-110/-103
PACAP up-regulation
B - Rat promoter
TGGCCTTCATGAGTCA TGACGTTT
PKA dependent up-regulation
Major transcription start sites (-110 -97)
+1
ATG-352/-346
TACAGTTACACT
LHX3
GATA2
LHX3
ISL1
P-LIRE
-873/-852
LHX3
ISL1
-109/-102-243/-235-336/-330
OCT1
NFY
TTCATTAAGGCTAATTGGA
-354/-345
-245/-237-368/-357
TAATTGGATAAT
CACGTTCACTTGCATCTG
E-box2
-247/-242
E-box3
-270/-265
E-box1
-164/-159
CLOCKCLOCK
MASH1
CREBSF1NEUROD1AP1 PITX1AP1 FOXL2
SMAD3/4
PROP1 OTX2 AP1 CREBSF1?
SURG I
-354/-347
FIGURE 2 | Response elements identified within the mouse and
rat promoters.The schema summarizes the functional elements
characterized on mouse (A) and rat (B) promoters. These elements are
involved in tissue-speciﬁc expression in gonadotrope cell lines, some
of them being also involved in activin-, GnRH-, and PACAP-dependent
regulation. Note that response elements directing gonadotrope-speciﬁc
expression of the rat promoter are located within 1000 bp 5′ upstream
of the ATG codon whereas those of the mouse promoter are conﬁned
within the most proximal 400 bp. The numbering is relative to the
translation start codon, the adenine being considered at position +1. This
numbering may therefore be different from that used in the original
publications.
the adult pituitary notably Cga, Lhb, Fshb, Tshb, Gh, Prl, Pomc,
and Gnrhr (Drouin et al., 1998). PITX1 activates the Gnrhr pro-
moter by interacting with c-JUN in the AP1 complex and by
binding to several low afﬁnity response elements scattered within
the −370/−326 region of the mouse promoter that includes the
AP1 response element (Jeong et al., 2004). Octamer-binding tran-
scription factor 1 (OCT1, formally POU2F1) belongs to the other
members of homeodomain transcription factors that regulate the
Gnrhr promoter activity. This was demonstrated by several con-
vergent approaches including targeted mutagenesis coupled with
gel-shift assays and transient transfection in gonadotrope cell lines,
chromatin immunoprecipitation (ChIP) assay, and short interfer-
ing RNA strategy (Kam et al., 2005). Together with the discovery
of the OCT1 response element that contains a core TAAT motif at
position −352/−349, a functional binding site for nuclear factor Y
(NFY)was identiﬁed in the course of this study. It partially overlaps
the OCT1 response element. Both transcription factors contribute
to the tissue-speciﬁc activity of the mouse Gnrhr promoter. Sev-
eral other TAAT motifs are present in the sequence of the mouse
promoter. One of them, located at position −164/−159, mediates
OCT1 trans-acting stimulation of Gnrhr promoter in addition
to the distal OCT1 interacting motif (Lents et al., 2009). Addi-
tional homeodomain factors are involved in promoter activity.
LHX3 that belongs to the LIM homeodomain (LIM-HD) proteins
is expressed in the early stages of pituitary ontogenesis at E9.5
and its expression persists in the adulthood (Ericson et al., 1998).
Similarly to PITX1, LHX3 is involved in the expression of several
pituitary marker genes. An ATTA motif located at −360/−357
was found to mediate the mouse Gnrhr promoter responsiveness
to LHX3. Also, the presence of LHX3 on the mouse promoter was
demonstrated in vivo by ChIP assay (McGillivray et al., 2005). A
complementary study showed that responsiveness to LHX3 was
further dependent on a second TAAT motif located only 4 bp
downstream (Cherrington et al., 2006). The integrity as well as the
speciﬁc helical orientation of the two motifs are required for full
LHX3 activity.
E-box transcription factors. Seven non-canonical E-boxes have
been identiﬁed along the Gnrhr promoter sequence suggesting
that basic/helix-loop-helix (b/HLH) transcription factors might
be involved in tissue-speciﬁc promoter activity. b/HLH tran-
scription factors (124 in numbers in mouse) have been classiﬁed
into six groups based on their evolutionary relationship, protein
structure characteristics, and sequence binding afﬁnities (Li et al.,
2006). Four of them, belonging to class A, B, and C, are sus-
pected to modulate the activity of the mouse Gnrhr promoter.
Indeed, mutation of each E-box in the mouse promoter resulted
in full or severe decrease in promoter activity as measured by
transient transfection assays using the αT3-1 gonadotrope cell
line (Resuehr et al., 2007). One at least out of the three most
Frontiers in Endocrinology | Neuroendocrine Science December 2012 | Volume 3 | Article 162 | 4
“fendo-03-00162” — 2012/12/11 — 20:28 — page 5 — #5
Schang et al. Gnrhr promoter regulation in mammals
proximal E-boxes (E-box 1, 2, and 3), binds the CLOCK (cir-
cadian locomotor output cycles kaput) transcription factor as
demonstrated by ChIP assay. This strongly suggested that the
mouse promoter is under the control of CLOCK/BMAL1 (brain
and muscle arnt-like protein 1) heterodimer. In addition, tran-
scripts encoding Drosophila homolog of period 1 (PER1), PER2,
cryptochrome 1 (CRY1), and CRY2 were detected, signifying
that dynamic inhibition by CRY/PER of CLOCK/BMAL1-directed
gene transcription may take place in this gonadotrope cell line.
Although the actors of the molecular loop essential for rhyth-
mic timekeeping are all present, circadian rhythms of Gnrhr
expression were not observed in cultured gonadotrope αT3-1
cells. Subsequent study considering E-box transcription factors
has demonstrated the involvement of two other b/HLH tran-
scription factors, neurogenic differentiation 1 (NEUROD1) and
mammalian achaete-scute homolog 1 (MASH1), that both inter-
act with E-box 3, suggesting that the CLOCK/BMAL1 heterodimer
bind to either E-box 1 or 2 but not to E-box 3 (Cherrington
et al., 2008). Interestingly, the αT3-1 gonadotrope cell line pref-
erentially expresses NEUROD1 whereas LβT2 cells preferentially
express MASH1. Consequently, Gnrhr E-box 3 binds NEUROD1
from αT3-1 cells, but binds MASH1 from LβT2 cells. This differ-
ence may be related to the differentiation state of these cell lines as
mentioned above.
The rat promoter (Figure 2B)
SF1, CRE, SAP, and AP1 elements in the proximal active domain.
The 5′ ﬂanking sequence of the rat promoter has been successively
isolated by Reinhart et al. (1997) and by Pincas et al. (1998) in our
laboratory. Comparative analyses reveal 82–84% sequence iden-
tity with the corresponding 1.9 and 1.2 kbmouse promoter region.
Sequencehomology iswell illustratedbydotmatrix pairwise align-
ment of rat versus mouse sequence (Figure 3A). The analysis
further reveals full lack of homology beyond 2.1 kb, suggesting
that master regulatory domains in rodents are constrained within
2 kb upstream of theATG codon. Furthermore, the transcriptional
start sites appear similarly clustered within the 110 bp proximal
region. A ﬁrst set of major sites is located between −110 and −103,
depending on the authors and a second set of both major and
minor sites is located around position −30. The rat promoter
was proved to be strongly active in αT3-1 and LβT2 gonadotrope-
derived cells as well as in GT1-7 hypothalamic-derived cell line.
Within the proximal domain, two elements that are identical to
the AP1 (−352/−346) and SF1 (−245/−237) response elements
of the mouse promoter are required to mediate gonadotrope-
speciﬁc activity (Pincas et al., 2001a). However, despite these
remarkable similarities, the rat promoter displays functional char-
acteristics that distinguish it from the mouse promoter. Two
additional response elements are required in the proximal active
domain for full cell-speciﬁc activity (Granger et al., 2006) a CRE
(cAMP response element) element (−110TGACGTTT−103) that
binds CRE binding protein (CREB) with a lower afﬁnity than the
consensus TGACGTCA sequence (Pincas et al., 2001b) and an ele-
ment located at −252/−245 that binds a yet unidentiﬁed factor
referred to as SAP for SF1 adjacent protein. Despite its immedi-
ate proximity with the SF1 response element, the SAP element
acts independently of SF1. Furthermore, a GRAS-like element is
present in the rat promoter but was proved inactive despite the
close sequence identity with its mouse counterpart (Pincas et al.,
2001a; Cherrington et al., 2005).
Homeodomain factor response elements in the distal and proxi-
mal regulatory domains. The distribution of response elements
along the promoter constitutes the most important difference
between the rat and mouse species. In contrast with the mouse
promoter where all known response elements are clustered within
the 500 bp proximal region, an additional regulatory region
containing a bipartite enhancer that we named Gnrhr-speciﬁc
enhancer (GnSE) lies on a more distal part of the rat promoter
(−1135/−753). Two major response elements located at posi-
tions −994/−960 and −871/−862 are responsible for GnSE action
(Pincas et al., 2001a; Granger et al., 2006). Interestingly, GnSE
activity is dependent onboth cellular andpromoter contexts. Max-
imal activity required the presence of the SF1 response element
that lies on the proximal promoter domain, 600 bp downstream.
Thus, the GnSE belongs to a class of promoter-speciﬁc enhancers,
capable of acting at a distance as classical enhancers do, but requir-
ing a speciﬁc context, in our case, a SF1 element containing
promoter. Regarding the proximal GnSE element (−871/−862), it
was found to bind the pair of LIM-HD proteins LHX3 and ISL1
(Granger et al., 2006). This was demonstrated by several conver-
gent approaches, notably using overexpression of the LIM-HD
proteins and a LHX3 dominant negative in co-transfection assays,
gel-shift and super-shift assays, andDNAafﬁnity chromatography.
This element displays high sequence identity in the antisense ori-
entation with the −363/−342 region of the mouse promoter that
was itself shown to interact with LHX3 (McGillivray et al., 2005;
Cherrington et al., 2006). Using antibodies against LHX3 and ISL1
in ChIP assays, we were able to show that the mouse sequence did
recruit ISL1 in addition to LHX3 (Schang et al., 2012b) as already
demonstrated by McGillivray et al. (2005). Nevertheless, deletion
of the LIM-HDresponse element in the rat promoter does not fully
abolish the trans-acting effect of the ISL1/LHX3 pair. This led us
to identify the upstream element of the GnSE as a second LIM-HD
response element. It displays similar properties and speciﬁcity as
the ﬁrst characterized one (Schang et al., 2012b). These elements
were then referred to as proximal and distal LIM-HD response ele-
ments, P-LIRE and D-LIRE, respectively. Finally, recent work from
our laboratory has permitted to the identiﬁcation of a prophet
of PIT1 (PROP1)/orthodenticle drosophila homolog 2 (OTX2)
response element in the proximal regulatory domain of the rat
promoter, located at −368/−357. Interestingly, OTX2 (or OTX1)
stimulates promoter activity in synergy with PROP1 by interacting
with this element in gonadotrope-derived cell lines. In contrast,
in non-gonadotrope cells, notably in the neutral Chinese ham-
ster ovary (CHO) cell line, OTX2 acts synergistically with CREB
through another OTX2 response element involving a ATTA core
motif located at position −163/−160, close to the CRE element
(Schang et al., 2012a).
Negative regulatory elements in the proximal part of the mouse
promoter
As underlined above, the GH3 lactosomatotrope-derived cell line
expresses the mouse promoter at a low but detectable level. The
www.frontiersin.org December 2012 | Volume 3 | Article 162 | 5
“fendo-03-00162” — 2012/12/11 — 20:28 — page 6 — #6
Schang et al. Gnrhr promoter regulation in mammals
FIGURE 3 | Sequence comparison of Gnrhr promoters in different
mammalian species. (A) Dot matrix representation of pairwise alignment of
rat versus mouse (left panel) or human (right panel) sequences. A strong
sequence conservation between mouse and rat 5′ upstream ﬂanking regions
extends over 2 kb whereas that between rat (or mouse) and human
sequences is limited to a proximal 0.5 kb region upstream of the ATG codon.
Relaxed sequence identity between rat and human sequences is further
observed between 0.5 and 1.2 kb upstream of the ATG codon. (B) Multiple
sequence alignment of mammalian Gnrhr proximal promoters. Blocks of full
identity are highlighted in gray. Some motifs of interest are boxed in the
sequences of the species where they have been characterized (e.g., SURG1
in the mouse, AP1 in rat and mouse). Note that the SF1 response element
characterized in the rat and mouse promoter sequences (−243/−235) is
particularly well conserved among species contrasting with the human SF1
response element (−134/−142). The latter appears to be shared by bovine,
porcine, ovine and canis species but not by rat and mouse.
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stably transfected GGH(3) cell, ﬁrst designed in order to eval-
uate GnRH action, was thereafter used to identify the elements
that allow constitutive expression in this non-gonadotrope, SF1-
lacking cell line (Maya-Nunez and Conn, 1999). A CRE element
(−109 5′-TGACGTTT-3′ −102) contributed to basal promoter
activity, suggesting that constitutive activation of the PKA-
dependent signaling pathway may also participate in cell-speciﬁc
activity in pituitary gonadotropes as well as in other GnRHR
expressing tissues. Importantly, several negative regulatory regions
were identiﬁed (−213/−207; −268/−259; −354/−342) that may
serve to repress the activity of the Gnrhr in non-gonadotrope
pituitary cells. Among them the −268/−259 (5′-TCTGCTGA-
3′) region is strictly conserved among bovine, porcine, ovine,
canis, human, rat, and mouse sequences (Figure 3B). How-
ever, the inhibitory effects of these sequences are modest and
cannot account for the whole lack of Gnrhr expression in non-
gonadotrope pituitary cells. Furthermore, they partially overlap
regulatory regions characterized as positive in a gonadotrope cell
context.
RESPONSE ELEMENTS INVOLVED IN TISSUE-SPECIFIC MOUSE AND
RAT PROMOTER ACTIVITY ARE ALSO INVOLVED IN REGULATION BY
EXTRA-CELLULAR SIGNALS
It is often noticed that tissue-speciﬁc transcription factors par-
ticipate either directly or as co-regulators in the modulation of
promoter activity by extra-cellular signals. This is also true for
the rodent Gnrhr since, as we shall see in more detail below, SF1 is
involved inPACAP- andPKA-regulated activity,AP1 in the homol-
ogous up-regulation by GnRH, and GRAS in the up-regulation by
activin.
GnRH homologous up-regulation in gonadotrope-derived cells
(Figure 4)
Two independent studies using transient transfection in αT3-1
cells demonstrated a time- and dose-dependent increase in the
activity of the mouse Gnrhr promoter under GnRH treatment
(Norwitz et al., 1999b; White et al., 1999). By using 3′ and 5′
deletion analyses combined with functional transfection stud-
ies, White et al. (1999) showed that a 54 bp fragment extending
from −370 to −326 and thus including the AP1 element was
sufﬁcient to mediate GnRH response when placed upstream of
a minimal heterologous promoter. Further analysis by Norwitz
et al. (1999a) using linker scanning mutagenesis led to identifying
two sequences of 8 bp, SURG-1 (sequence underlying responsive-
ness to GnRH-1; −354/−347) and SURG-2 (−338/−331) that are
necessary for full GnRH responsiveness (Figure 3B). The SURG-2
element corresponds to theAP1 element and is absolutely required
since mutations within this sequence totally abolished GnRH-
induced stimulation of promoter activity whereas mutations
within the SURG-1 element (5′-GCTAATTG-3′) only attenu-
ated the response. Based on targeted mutagenesis of each of the
GRAS, AP1, and SF1 elements that compose the tripartite basal
enhancer, the study byWhite et al. (1999) has led to a rather similar
conclusion regarding the AP1 element involvement. Both stud-
ies, using antibodies directed against conserved protein domains
of either the JUN or FOS families in electrophoretic mobility
shift assays strongly suggest that an AP1/DNA complex mediates
GnRH homologous up-regulation. The MAPK kinase (MEK1/2)
inhibitor PD98059 abrogates both GnRH-induced stimulation of
promoter activity and GnRH-induced phosphorylation of extra-
cellular signal-regulated kinases (ERK) 1 and 2 (White et al., 1999)
and of c-Jun N-terminal kinase (JNK; Ellsworth et al., 2003b).
GnRH induction of mouse Gnrhr promoter activity may thus
require functional activation of a PKC-dependent pathway that
involves the ERK- or JNK-signaling cascade or both and ulti-
mately converges to AP1. However, accurate analysis of the
intracellular events induced by GnRH treatment of αT3-1 cells
strongly suggested that the JNK-signaling cascade is predomi-
nantly involved (Ellsworth et al., 2003b). Accordingly, in pituitary-
targeted ERK1/2 double-knockout mice, Gnrhr expression was
not altered as compared with wild-type animals (Bliss et al.,
2009), suggesting that ERK signaling is not primarily involved in
gonadotrope-speciﬁc expression of the Gnrhr. Moreover, the acti-
vation of the JNK-signaling cascade induced post-translational
modiﬁcations of FOSB and JUND that led to increased binding
of both factors on the SURG-2, the AP1 response element of the
Gnrhr promoter (Ellsworth et al., 2003b). More recently, the fac-
tors that interact with SURG-1 have been identiﬁed as OCT1 and
NFY. They are not only involved in the tissue-speciﬁc expression
as mentioned above but also in GnRH homologous up-regulation.
ChIP assays demonstrated that both factors are recruited on the
mouse promoter in a time-dependent manner after GnRH treat-
ment (Kam et al., 2005). It is important to point out that, in the
context of the 600 bp mouse promoter, the adenylate cyclase acti-
vator forskolin inhibits GnRH-induced stimulation, suggesting a
cross-talk between these two pathways (White et al., 1999). How-
ever, in the context of the chimera promoter made up with the
mouse −370/−326 bp promoter fragment linked to the mini-
mal GH heterologous promoter, forskolin is inefﬁcient even if
the GnRH response is maintained. This may indicate that the
cross-talk takes place at the promoter level and requires response
element(s) that are present within the 600 bp mouse promoter
fragment and absent from the −370/−326 bp promoter fragment,
notably the CRE element located at −109/−102 bp.
GnRH homologous up-regulation in non-gonadotrope cells (Figure 4)
The GnRHR is known to be expressed in several extra-pituitary
tissues, notably in some areas of the brain, as well as in gonads and
placenta. In this regard, it is important to consider the modalities
of expression and regulation of the Gnrhr in cells distinct from
gonadotropes. The availability of the stably transfected GGH3
cell line has permitted evaluating GnRH action on the transfected
mouse promoter in a non-gonadotrope context. Consistent with
the data obtained with αT3-1 cells, the activity of the mouse
promoter was signiﬁcantly increased in GGH3 cells following
GnRH treatment (Lin and Conn, 1998). Subsequent analysis sug-
gested that GnRH action is likely mediated by both PKA- and
PKC-dependent signaling pathways (Lin and Conn, 1998, 1999;
Maya-Nunez and Conn, 1999, 2001). Accordingly, GnRH stim-
ulation was partly prevented by the adenylate cyclase inhibitor
SQ22536 while treatment with the PKC inhibitor GF109203X led
to nearly complete blockade. These data are in accordance with
other results obtained using cholera toxin or cAMP analogs as
well as following treatment with phorbol ester (Lin and Conn,
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FIGURE 4 | Signaling pathways in the homologous up-regulation of the
mouse GnRHR promoter by GnRH in gonadotrope and non-gonadotrope
cells. In αT3-1 cells, GnRH-induced activation of the PKC-dependent pathway
stimulates promoter activity through the MAP kinase signaling pathway,
involving ERK1 and ERK2. Receptor-independent activation of the
PKA-dependent pathway inhibits GnRH-stimulated promoter activity. In GGH3
cells, GnRH induces the simultaneous activation of the PKC and
PKA-dependent pathways for stimulating promoter activity. Constitutive
activation of the MAP kinase signaling pathway, involving ERK1 and ERK2,
inhibits basal and GnRH-stimulated promoter activity. The three elements,
SURG-1, SURG-2, and CRE therefore participate in GnRH up-regulation in
both αT3-1 and GGH3 cells. In αT3-1 cells, the positive involvement of SURG-1
and SURG-2 have been demonstrated whereas that of the CRE element is
only suspected to be inhibitory. In GGH3 cells, the CRE element is required
for promoter stimulation and appears as the ultimate target of the
PKA-dependent pathway. AP1, also referred to as SURG-2 is only potentially
involved essentially because GnRH also activates the PKC-dependent
signaling pathway in these cells.
1998, 1999). It is important to specify that all these treatments
resulted in the stimulation of the MAPK pathway in GGH3 cells
(Han and Conn, 1999). However, agents that inhibit the activa-
tion of the MAPK pathway such as the drug PD98059 or ERK1
and ERK2 mutants together increased both tissue-speciﬁc and
GnRH-stimulated promoter activity. Conversely, transfection of
vectors expressing agents that mimic the activation of the MAPK
pathway such as Raf1 or wild-type ERK1 and ERK2 inhibited
tissue-speciﬁc and GnRH-stimulated promoter activity. Alto-
gether, these data indicate that activation of the MAPK pathway
is inhibitory in the lactosomatotrope GGH3 cell line whereas it
is stimulatory in gonadotropes. Furthermore, GnRH action in
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GGH3 cells resulted in two opposite effects on the activity of the
mouse Gnrhr promoter: a negative effect through the activation
of the MAPK pathway and a positive one through the activa-
tion of PKA- and PKC-dependent pathways. The CRE element
(−109/−102) that is involved in tissue-speciﬁc activity seems to
be also involved in the GnRH and PKA-dependent regulation. The
stimulatory effect of GnRHwas indeed partially abolished and that
of cAMP analog fully abrogated by targeted mutations of the CRE
element. It is then rather probable that GnRH action also occurs
through the SURG2 element in GGH3 cells.
Activin up-regulation
Activin, a member of the transforming growth factor-β superfam-
ily, has ﬁrst been shown to enhance the GnRH-induced FSH and
LH release and to enhance the rate of GnRHR synthesis in rat pitu-
itary cells (Braden and Conn, 1992; Weiss et al., 1993). This led to
question its potential action at the transcriptional level. Exogenous
activin B treatment of αT3-1 cells was shown to increase Gnrhr
promoter activity as demonstrated by nuclear run-off assays or
after transient transfection of the 1.2 kb mouse promoter linked
to the luciferase reporter gene (Fernandez-Vazquez et al., 1996).
However, since αT3-1 cells and pituitary gonadotropes both pro-
duce activin B, responsiveness to activin has then been mainly
monitored by follistatin-induced inhibition of activin action in
subsequent analyses (Duval et al., 1999). Using transient trans-
fection in αT3-1 cells, follistatin inhibition of promoter activity
was demonstrated to be mediated through the GRAS element.
Indeed, mutation of this motif abrogated follistatin inhibition
whereas alteration of the SF1 or AP1 elements was minimally
efﬁcient. Consistent with these results, three copies of the GRAS
element were sufﬁcient to confer activin responsiveness to a
minimal heterologous promoter. The GRAS motif also exhibits
sequence similarities with the element (GTCTAGAC) that binds
the receptor-activated SMAD2/SMAD3 and the common SMAD4
(Stopa et al., 2000), involved in activin signaling (Walton et al.,
2012). The autocrine/paracrine action of activin also explains
why the GRAS motif has been classiﬁed as a paracrine/autocrine
cell-speciﬁc response element. Comparison with the rat promoter
sequence that does not exhibit activin responsiveness led to the
characterization of a second region involved in activin-mediated
up-regulation of the mouse promoter, a region referred to as
“downstream activin regulatory element” or DARE (Cherring-
ton et al., 2005). This 18 bp-long region lies between −366 and
−349 and overlaps LHX3, OCT1, and NFY response elements.
However, none of these factors seems to be involved in activin
responsiveness. The integrity of the two TAAT motifs identiﬁed
in this sequence was mandatory for functional DARE. Further-
more, appropriate helical orientation of this region relatively to
the GRAS element located 20 bp downstream is required suggest-
ing that factors that bind to DARE interact with GRAS binding
factors (SMAD, AP1, FOXL2; Cherrington et al., 2006).
Norwitz et al. (2002a,b) have investigated the potential synergy
between GnRH and activin treatment on the mouse promoter
activity. They found that activin was able to increase the stim-
ulatory effect of GnRH by approximately twofold. Interestingly,
deletion of the promoter region that contains the GRAS element
as well as mutation that alters the 5′ part of the GRAS element
abrogated the effect of activin on GnRH stimulation. They also
showed that overexpression of SMAD4 together with SMAD2
or SMAD3 increased both tissue-speciﬁc promoter activity and
GnRH homologous up-regulation. However, it remains to be
established if mutation of the presumed Smad binding element
(SBE box −393/−386) in the GRAS element may prevent the
stimulatory effect induced by SMADoverexpression. Competition
and super-shift experiments further indicated that a second factor,
belonging to the AP1 family, may bind the 3′ part of the GRAS ele-
ment, suggesting that JUN/FOS related factors and SMAD protein
functionally interact.
PACAP up-regulation
Speciﬁc type 1 receptors for PACAP are present in gonadotrope
cells of the anterior pituitary gland as well as in mouse
gonadotrope-derived αT3-1 cells. By transient transfection in
αT3-1 cells, Pincas et al. (2001b) provided evidence that PACAP
stimulates rat Gnrhr promoter activity. The EC50 of this stimula-
tion was compatible with PACAP activation of the cyclic AMP-
dependent signaling pathway and, consistently, co-transfection
of an expression vector expressing the PKA inhibitor caused
reduction in PACAP – as well as cholera toxin –stimulated pro-
moter activity. Deletion and mutational analyses indicated that
PACAP activation necessitated a bipartite response element that
consists of a ﬁrst region (−272/−237) termed PACAP response
element (PARE) I that includes the SF1-binding site and a sec-
ond region (−136/−101) referred to as PARE II that contains the
CRE (TGACGTTT). Gel-shift experiments revealed that SF1 and
SAP together bind to PARE I while a protein immunologically
related to the CREB interacted with PARE II. Altogether, these
ﬁndings indicated that PACAP regulates the rat Gnrhr at the tran-
scriptional level in αT3-1 cells. Interestingly, the mouse promoter
was similarly proved to be regulated by PACAP (Sadie et al., 2003).
However, the response elementswerenot identiﬁed, norwere those
involved in the PKA-induced stimulation of the mouse promoter.
Notably, the ability of the CRE located at −109/−102 (i.e., equiv-
alent to the rat promoter one) to mediate the PKA-dependent
stimulation of the mouse promoter was not assessed. Neverthe-
less, two other response elements were shown to modulate PKA
responsiveness (Sadie et al., 2003), the SF1 response element and a
newly identiﬁed response element located at −15/−7, close to the
translation initiation site (ATG). Both elements were able to bind
NUR77 (NR4A1) and SF1 and exerted opposite effects. Mutation
of the element close to the ATG codon together with overexpres-
sion of SF1 dramatically ampliﬁed PKA-induced stimulation. In
contrast, overexpression of NUR77 repressed PKA-dependent reg-
ulation, most probably through the −15/−7 element. PACAP has
been shown to stimulate follistatin (Fst) gene expression which
restrains activin signaling and thus represses Fshb and Gnrhr
expression as well as other activin-responsive genes. Therefore,
in mouse gonadotrope cells, the PACAP direct stimulatory effect
on Gnrhr promoter may be weakened by the indirect inhibitory
action of PACAP on activin-stimulated promoter activity. The rat
promoter is not submitted to this down-regulation because both
the GRAS element and the DARE region are inactive. Whether
PACAP regulation also occurs in vivo and is a common trait in
mammals remains to be elucidated however.
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FUNCTIONAL CHARACTERISTICS OF THE HUMAN Gnrhr PROMOTER
IN VITRO
The human Gnrhr promoter has been independently isolated
by two groups (Fan et al., 1995; Kakar, 1997). It displays sev-
eral features that distinguish it from rodent promoters (Cheng
and Leung, 2005). Firstly, a signiﬁcant sequence identity with
the above-described promoters does not extend beyond approx-
imately −1200 bp from the ATG codon (Figure 3A). Secondly,
in contrast to the rodent promoters, the transcription start sites
are located far upstream of the ATG codon and disperse within
two domains localized between −578 and −826 and between
−1347 and −1751, indicating the existence of two core promoter
regions (Fan et al., 1995; Kakar, 1997). A further difference with
mouse and rat promoters is the presence of several TATA boxes
well scattered among the transcription start sites, suggesting that
transcription initiation occurs through different mechanisms in
rodent and human.
Given that GnRHR is expressed in several tissues in addition
to the pituitary gland, functional studies with the human pro-
moter have been performed in non-pituitary cell lines, notably
cells derived from placenta, endometrium, trophoblast, and ovary.
This strategy has also been motivated by the absence of pituitary
cell line of human origin. These studies led to the discovery of
several positive and negative regulatory regions, the efﬁcacy of
which being strongly dependent on the considered cell line. They
essentially conﬁrmed the existence of distinct promoters within
the 2 kb human 5′ ﬂanking sequence.
The proximal core promoter is predominantly active in
gonadotrope-derived cells (Figure 5A)
Following transfection in αT3-1 cells, it appeared that crucial ele-
ments are located in the close vicinity of the translation start codon
because the −173/+1 deletion abolished promoter activity (Ngan
et al., 1999; Kang et al., 2000). Targeted mutagenesis of a SF1
response element located at −142/−134 (5′-CAGGGACAA-3′)
altered overall promoter strength suggesting that it is likely con-
tributing to the gonadotrope-speciﬁc activity. The involvement
of SF1 has been further evidenced by electrophoretic mobil-
ity shift and super-shift assays as well as by overexpression of
SF1 (Ngan et al., 1999). However, silencer elements present in
the middle part of the human promoter (−1018/−707) weaken
promoter strength. Indeed, 5′ deletion to −707 increased tissue-
speciﬁc activity in αT3-1 cells, the deleted promoter (−707/+1)
being approximately threefold more active than the entire pro-
moter (−2200/+1; Cheng and Leung, 2001). These data are
in agreement with the existence of a proximal core promoter
region (−816/−577) previously documented (Fan et al., 1995) and
with the presence of a positive regulatory region (−771/−557)
identiﬁed by 3′ deletion analysis (Kang et al., 2000). This also
suggests that positive regulatory regions either overlap the core
promoter region or are situated downstream from the transcrip-
tion start sites as is the SF1 element cited above. Subsequent
analysis by scanning mutations in αT3-1 cells has allowed precise
delimitation of this proximal promoter that extends from −607
to −568. It contains two pyrimidine-rich initiator elements
(−602/−597 and −589/−584) that bind similar proteins notably
TFIID (Hoo et al., 2003). The distal promoter of the human gene
is constitutively active in both gonadotrope and non-pituitary cell
lines (Figure 5B).
The existence of a distal promoter active in non-pituitary cell
lines has been strongly suggested in the early study by Kakar
(1997). In this work, it is indeed shown that the −2300/−1020
human ﬂanking sequence is highly active in human endometrial
(HEC-1A) and breast tumor cell (MCF-7) lines. This upstream
promoter was further characterized in either gonadotrope or non-
pituitary cells by Ngan et al. (2000) and Cheng et al. (2001a),
respectively. It appears to be less active in αT3-1 pituitary than
in JEG-3 placental cells (Cheng et al., 2001a) and thus contrasts
with the core proximal promoter that displays opposite character-
istics. Also, the distal promoter seems to be more ubiquitous than
the proximal promoter since it was active in gonadotrope, ovarian,
endometrial, mammary, placental, and kidney cells. The in-depth
analysis of the distal promoter in gonadotrope-derived αT3-1 cells
(Ngan et al., 2000) and placental JEG-3 cells (Cheng et al., 2001a)
reveals cell-speciﬁc differences.
In gonadotrope-derived cells, the active elements of the
upstream promoter are located within a −1705/−1674 region
and are not functional in the reverse orientation. They consist
of a pyrimidine-rich initiator (−1685/−1676) and additional up-
stream motifs (−1705/−1687) that include a CCAAT box. Multi-
ple proteins ranging from 40 to 54 K are capable of binding this
upstream promoter. Interestingly, a downstream silencer element
(−1674/−1577) prevents upstream promoter activity, at least in
gonadotrope cells. This silencer is efﬁcient only when positioned
downstream of the promoter in either reverse or forward orien-
tation. Two sequence-speciﬁc repressor motifs of 28 and 8 bp
(−1670/−1643 and −1630/−1623) are essential for silencer activ-
ity as evidenced by linker-scanning mutagenesis and gel mobility
shift assays (Ngan et al., 2001).
In JEG-3 and IEVT placental cell lines, a similar organization
seems tooccur, combiningpositive regulatory sequence anddown-
stream silencer, however with different localization and distinct
response elements (Cheng et al., 2001a). The placental cell-speciﬁc
upstream promoter is located within a −1737/−1346 region
and thus overlaps the gonadotrope cell-speciﬁc promoter. In
JEG-3 cells, four motifs related to OCT1 (−1718/−1710),
CRE (−1649/−1641), GATA (−1602/−1597), and AP1
(−1518/−1511) response elements are contributing to promoter
activity. The characterization of these motifs has been further
assessed by gel mobility shift and antibody super-shift assays. The
downstream silencer is located between −1017 and −771 and
abrogates upstream promoter activity in a manner similar to what
is observed with the gonadotrope promoter. The silencer was fur-
ther characterized in the context of the −1300/−1018 promoter
described below. Under these conditions, it appeared that most
of the silencing activity of this negative regulatory element resides
in an octamer responsive sequence activated by OCT1 (Cheng
et al., 2002b).
Distal promoter usages in granulosa and neuronal cell lines
A third distal promoter was characterized in human ovarian
granulosa-luteal cells. It extends from −1300 to −1018 and
exhibited the highest promoter activity in SVOG-4o and SVOG-
4m immortalized granulosa-luteal cells (Cheng et al., 2002a).
Frontiers in Endocrinology | Neuroendocrine Science December 2012 | Volume 3 | Article 162 | 10
“fendo-03-00162” — 2012/12/11 — 20:28 — page 11 — #11
Schang et al. Gnrhr promoter regulation in mammals
Silencer
-1018/-707
AP1/CRE
-568/-561
AP1/CRE
-340/-333
SF1
-142/-134
PRE
-535/-521
+1
ATG
PACAP and PKA 
dependent regulation
Progesterone up (placental cells) and 
down (gonadotrope cells) regulation
Human proximal promoter
(transcription start sites -826/-578)
AP1
-1000/-994
GnRH up (placental cells) and
down (gonadotrope cells) regulation
Silencer
Human distal promoter
-2300 -1020
28-bp element
-1670/-1643
8-bp element
-1630/-1623
OCT1 CRE GATA AP1
-1017  Silencer -771
-1718/
-1710
-1649/
-1641
-1602/
-1597
-1518/
-1511
a - Gonadotrope cells
b - Placental cells
-2300
A
B
AP1
-130/-124
Estradiol-mediated down regulation
in ovarian and breast cancer cells
c - Granulosa cells
Promoter -1300/-1018
C/EBP C/EBPGATA
-1244/
-1232
-1176/
-1168
-1157/
-1144
OCT1
-1016/
-1008
-2300
PACAP up-regulation
-1676/-1648
TSS TSS
-1397 -1375
TSS
-769
TSS
Promoter -1737/-1346
Gonadotrope-specific promoter (-607/-568) with two Inr at -602/-597 and -589/-584
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However, it was also active in placental, ovarian, and gonadotrope
cells. Two CCAAT enhancer binding protein (C/EBP) located
at −1244/−1232 and −1157/−1144 and one GATA response ele-
ment located at −1176/−1168 were required for full promoter
activity because simultaneous mutations of these three elements
led to more than 75% decrease in promoter activity in granulosa
cells. Interestingly, the same mutations induced minimal or no
signiﬁcant decrease in promoter activity in ovarian, placental, and
gonadotrope cells suggesting that different response elements and
different transcription factors are involved in these cell contexts.
Human GnRHR was further expressed in the human cere-
bellar medulloblastoma cell line TE-671. In these neuronal cells,
promoter activity was dependent on an upstream region located
between −2197 and −1018. Important cis-acting regulatory ele-
ments were identiﬁed at −1300/−1018 and −2197/−1900, as
deletion of either region induced a dramatic decrease in promoter
activity (Yeung et al., 2005).
REGULATION OF HUMAN PROMOTER ACTIVITY BY EXTRACELLULAR
SIGNALS (FIGURE 5)
Homologous up- and down-regulation by GnRH and the
PKC-dependent pathway
Surprisingly, when compared to rodents, a 6–24 h-long treatment
with 0.1 μM GnRH reduced activity of the 2.3 kb human GnRHR
promoter by 31–71% in αT3-1 cells. This inhibitory effect was
mimicked by phorbol ester and prevented by GnRH antagonists
or speciﬁc PKC inhibitors (Cheng et al., 2000) strongly suggest-
ing that GnRH action is mediated through receptor-dependent
activation of the PKC pathway. Subsequent 5′ deletion analyses
combined with site-directed mutagenesis revealed that an AP1
related element located at −1000/−994 (TTAGACA) is responsi-
ble for the homologous down-regulation of promoter activity by
forming an AP1 complex involving the c-JUN and c-FOS proto-
oncogenes. ThisAP1 element is unrelated to theAP1/CRE element
involved in tissue-speciﬁc expression. It isworth stressing that sim-
ilar GnRH treatment applied to placental JEG-3 or IEVT cell lines
led to signiﬁcant increases in promoter activity, contrasting again
with data obtained in gonadotrope-derived cells (Cheng et al.,
2000). The mechanisms underlying these positive and negative
regulations remain to be elucidated, notably whether differential
promoter usage (upstreamversus proximal)may be related to such
difference in GnRH regulation.
Up-regulation by PACAP and PKA-dependent pathway
The regulation of the human promoter by PACAP and the
PKA-dependent activation pathway has been investigated in two
different studies and led to the identiﬁcation of distinct regula-
tory domains located within either the upstream or the proximal
promoter, respectively (Cheng and Leung, 2001; Ngan et al.,
2001). The former study (Ngan et al., 2001) indicated that both
the gonadotrope cell-speciﬁc upstream promoter as well as the
downstream silencer are involved in PACAP and PKA-dependent
regulation. In support, PACAP treatment enhanced the formation
of a complex with the 28 bp sequence-speciﬁc repressor motif (see
above). Whether this may contribute to suppress silencer func-
tion and in turn to activate promoter remains to be demonstrated.
The mechanisms underlying this positive regulation are not yet
clearly identiﬁed. The latter study by Cheng and Leung (2001) led
to the conclusion that PACAP and CREs reside within a 412 bp
fragment (−577/−167) of the proximal promoter. Indeed, muta-
tion of the (−568/−561 and −340/−333)AP1/CRE related motifs
nearly abrogated the stimulation.
Up- and down-regulation by steroid hormones
Similarly to GnRH, progesterone treatment led to either inhibi-
tion or stimulation of promoter activity in gonadotrope versus
placental cells, respectively (Cheng et al., 2001b). A progesterone
binding site located at −535 to −521 has been shown to medi-
ate, at least partially, both the inhibitory and stimulatory action of
progesterone. Overexpression of the human progesterone receptor
A and B isoforms increased the negative effect of progesterone in
αT3-1 cells, whereas only B isoform mediated its positive action
in JEG-3 placental cells. It is important to point out that the A iso-
form mediated inhibitory action in both cell lines, suggesting that
the balance in the expression of A and B isoforms may be critical
for GnRHR expression in the pituitary. The involvement of the
progesterone receptor in binding the −535/−521 motif has been
further substantiated by gel-shift and antibody super-shift assay.
In OVCAR3 ovarian carcinoma and MCF7 breast carcinoma
cell lines, E2-induced repression of Gnrhr promoter activity
through an E2 receptor α (ERα)-mediated mechanism (Cheng
et al., 2003). This occurred in a dose- and time-dependentmanner,
the maximal effect being obtained at 10−8 M E2 after a 48 h-
long treatment (80% reduction of promoter activity). Repression
occurred via an AP1-like element located at position −130/−124.
This element was able to bind c-FOS and c-JUN but not ERα as
demonstrated by EMSA. DNA binding by ERα was not needed
for the E2 repression of Gnrhr promoter activity. Further exper-
iments strongly suggested that recruitment of AP1 and ERα to
CREB binding protein (CBP) was mutually exclusive leading to
inhibition of AP1-stimulated promoter activity by E2.
IN VIVO ANALYSIS OF THE MOUSE, OVINE, AND RAT
PROMOTERS IN TRANSGENIC MICE
Since in vitro studies of promoter functions often suffer from limi-
tationof the cellularmodels used in transient transfection analyses,
the next and complementary approach consists in analyzing pro-
moter activity in an in vivo context through the generation of
transgenic mice.
Several studies have beenpublished that use this procedure. The
initial study by McCue et al. (1997) demonstrated the homologous
up-regulation of Gnrhr promoter activity by GnRH. A 1900-
bp fragment corresponding the mouse Gnrhr promoter fused
to the luciferase reporter gene has been microinjected in mouse
embryos and mice harboring the transgene were selected. Analy-
sis of luciferase activity in various tissues showed that the fusion
gene was expressed essentially in the pituitary gland, to a 10-fold
lower level in the brain and to a limited extend in the testis. These
data are in agreement with those deduced from autoradiographic
studies using 125I-labeled GnRH or in situ hybridization (Jennes
et al., 1988, 1995; Leblanc et al., 1988; Ban et al., 1990; see review
in Jennes et al., 1997). Surprisingly, the expression of the trans-
gene was not detected in the ovary contrasting with a number of
studies reporting the presence of GnRHR in this tissue, speciﬁcally
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in granulosa cells of atretic follicles. Using an antibody directed
against GnRH, the authors further showed a decrease in trans-
gene expression in the pituitary gland but not in the brain or
testis. The GnRH antibody inhibitory action could be reversed by
a GnRH agonist treatment. As expected from in vitro studies, the
1900-bp promoter contains essential GnRH response elements.
However, E2 treatment of these transgenic mice did not alter the
activity of the transgene. This diverges with a number of reports
demonstrating that, in vivo, E2 increases GnRHR number and
steady-state level of Gnrhr mRNA in the pituitary (Hamernik et al.,
1995; Turzillo et al., 1995; Kirkpatrick et al., 1998).
The same group has thus reinvestigated this regulation with
novel lines of transgenic mice harboring a fusion construct con-
taining the ovine receptor gene promoter linked to the luciferase
reporter gene (Duval et al., 2000). Using either a 9.1 or a 2.7 kb
promoter, they ﬁrst showed that the ovine transgene displayed
the same tissue-speciﬁc expression as the mouse promoter. The
ovine transgene was indeed consistently expressed in the pitu-
itary, brain, and gonads across the three analyzed transgenic lines.
Pituitary expression was higher in females than in males whereas
ovarian expression was signiﬁcantly lower than the testicular
one. In agreement with results obtained with the mouse pro-
moter, immunoneutralization of GnRH reduced pituitary-speciﬁc
expression of the luciferase reporter gene in ovariectomized mice,
expression that could be restored by E2 treatment. Similar results
were observed in castrated, male transgenic mice. Finally, com-
bined treatments with GnRH agonist and E2 increased pituitary
expression of the luciferase fusion gene to an extent greater
than the sum of each individual treatment, suggesting synergistic
activation of the ovine promoter.
The third study involving transgenic mice was different in at
least two facets. Firstly, in this case, the reporter gene was the
simian virus 40 (SV40) large T antigen and, secondly, the mouse
promoter was the shortest used since it was 1.2-kb long only
(Albarracin et al., 1999). With this fusion construct, the result-
ing heterozygote transgenic female mice were infertile preventing
the generation of homozygote animals. Interestingly, all transgenic
animals developed large intracranial tumors by 4–5 months of age
that were of pituitary origin. As evidenced by in situ hybridization,
these tumors expressed the marker genes of the gonadotrope phe-
notype, i.e., GnRHR, glycoprotein hormone α-subunit as well as
FSHβ and LHβ subunits. The large T antigen was also expressed
in the pituitary tumors but neither in the gonads or in the brain.
This may indicate that the 1.2-kb, as compared with the 1.9-kb
promoter fragment, is not able to direct transgene expression to
sites other than the pituitary, notably brain and gonads. Surpris-
ingly, the expression of the SV40 large T antigen transgene driven
by the GnRHR gene promoter results in female-speciﬁc infertility
due to disruption of gonadotropin production and secretion even
before tumor development (Jeong et al., 2009).
In our laboratory, the 3.2 kb rat promoter was placed upstream
of the human placental alkaline phosphatase reporter gene (ALPP)
and inserted into the mouse genome. The resulting transgenic
mice expressed the ALPP exclusively in gonadotropes within the
pituitary gland (Granger et al., 2004). Transgene expression was
detected within the developing pituitary at E13.5 in some of the
cells that also expressed the Cga. It showed that Gnrhr is the
earliest marker of gonadotrope cell differentiation, before SF1 that
is detected at E14.5. At E15.5, ALPP expression was localized in
LHX3- and ISL1-immunoreactive positive cells in agreement with
in vitro data showing that these LIM-HD proteins are involved in
rat andmouse promoter activity. Importantly, the 3.2 kb promoter
was also able to direct ALPP expression to several brain areas, in
particular the hippocampus and the lateral septum, in agreement
with previous data (Jennes et al., 1988, 1995; Leblanc et al., 1988;
Ban et al., 1990; see review in Jennes et al., 1997). In contrast with
the pituitary gland, transgene activity in the hippocampus was
detected only after birth, increasing gradually until 14–20 days
after birth and then remaining at constant level until 60 days
after birth (Schang et al., 2011b). This occurred simultaneously
in ﬁbers extending from the hippocampus to the lateral septum,
suggesting that GnRHR may be involved in post-natal matura-
tion of the septo-hippocampal system. The same time-course was
observedbymeasuringGnrhr mRNAin rat hippocampusbyquan-
titative RT-PCR, indicating that transgene expression directed by
the rat promoter recapitulates rat endogenous Gnrhr expression
in a mouse context. Further experiments using transient trans-
fection of Gnrhr promoter luciferase fusion constructs in primary
culture of rat hippocampus cell revealed that a RE1-silencing tran-
scription factor (REST also known as NRSF)-like element located
at −2.5 kb may be involved in the inhibition of Gnrhr gene expres-
sion before birth. Finally, GnRH treatment of rat hippocampus
primary cell culture led to stimulation of several markers of neu-
rogenesis such as EGR1, synaptophysin, and spinophilin. Using
this transgenic mouse model, several additional sites of trans-
gene expression were detected, notably in the oculomotor pathway
(Schang et al., 2011a). Interestingly, transgene expression was also
detected in two functionally and evolutionary related organs, the
pineal gland and the retina. Again, the onset of transgene expres-
sion was speciﬁc to these tissues, being detected at E13.5 and E17.5
in the pineal gland and retina, respectively (Schang et al., 2012a).
In the pineal gland, transgene expression persisted until adulthood
whereas it strongly decreased in the retina. During development,
transgene expression was the strongest in the neuroblast cell layer
of the retina and less marked in the ganglion cell layer. In the
pineal gland, transgene expression was constantly observed in
approximately 50% of the cells whatever the developmental stage.
Finally, transgene expression was strongly detected in the testes of
transgenic mice in some Leydig cells (Schang et al., 2011a).
Recent studies involving functional genomic approaches have
shown that regulatory domains may be located within the gene
locus at several kilobases, either 5′ upstream or 3′ downstream
as well as within intronic regions. This is well demonstrated par-
ticularly for genes coding for transcription factors, notably SF1
(Shima et al., 2012 and references therein), or genes encoding
for factors involved in early developmental processes such as the
LIM-HD proteins LHX3 and ISL1 (Kappen and Salbaum, 2009;
Mullen et al., 2012). Conversely, other studies have shown that the
most important genetic regulation may be contained within only
1 kb 5′ upstream of the transcription start site, including informa-
tions regarding epigenetic modiﬁcations such as pattern of DNA
methylation (Lienert et al., 2011). Furthermore, species-speciﬁc
informations would be encoded into DNA sequence and appears
to prevail over species-speciﬁc cellular environment. A human
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chromosome introduced into a mouse cell line directs genetic and
epigenetic modiﬁcations as it does in a human cell context and
thus differently from its mouse counterpart (Wilson et al., 2008).
Therefore, data obtained using transgenic mice as well as those
described above must be considered bearing in mind the fact that
all regulatory sequences are not necessarily contained within the
5′ upstream region of the gene only, even if relatively short 5′
upstream sequences may contain master regulatory informations.
This could explain why the human GNRHR promoter responded
negatively while mouse or rat promoters are stimulated by GnRH.
To overcome these limitations, a double knock-in mice model
was recently developed. In this binary genetic approach, the Cre-
recombinase was inserted into the Gnrhr locus whereas the YFP
reporter gene, preceded by a ﬂoxed stop signal, was inserted into
the ubiquitously expressed ROSA26 locus. TheCre-mediated exci-
sion of the stop signal led to a constitutiveYFP expression in about
15% of the cells in the male anterior pituitary. Furthermore, the
ﬂuorescent signalwas only colocalizedwithLHβ and/or FSHβ sub-
units as demonstrated by immunohistochemistry. TheseYFP mice
have allowed single-cell analysis on living cells which have revealed
unexpected heterogeneity in the resting properties of gonadotrope
cells as well as in their secretory, electrophysiological, and calcium
responses to GnRH (Wen et al., 2008).
SF1, A PAN-SPECIES TRANSCRIPTION FACTOR CRITICAL FOR
GONADOTROPE-SPECIFIC EXPRESSION
An obvious conclusion that emerges from this overview of the
mechanisms involved in Gnrhr expression is the important role of
the orphan nuclear receptor SF1. It is undoubtedly involved in the
tissue-speciﬁc expression of the human,mouse, and rat GnRHR. It
is also likely involved in the tissue-speciﬁc expression of the ovine
gene since the promoter is strongly homologous to its human
counterpart. SF1 is crucial not only for tissue-speciﬁc expression
but also for the regulation by extracellular signals as evidenced
by PACAP and PKA-dependent regulations of the rat promoter.
This may be related to the other important functions of SF1 in
the tissue-speciﬁc and regulated expression of Cga and Lhb genes,
two other markers of the gonadotrope lineage. Consistent with
these data, the SF1 knockout mice exhibit impaired expression
of LHβ, FSHβ, and GnRHR in pituitary gonadotropes in addi-
tion to other major defects such as agenesis of the ventro-medial
hypothalamus, complete adrenal and gonadal agenesis and male-
to-female sex reversal with persistence of Müllerian structures in
male (Ingraham et al., 1994; Ikeda et al., 1995; Luo et al., 1995). To
bypass the inﬂuence of hypothalamic deﬁciencies inherent to this
transgenic model, SF1 has been inactivated speciﬁcally in the ante-
rior pituitary using the Cre-loxP system (Zhao et al., 2001). These
pituitary-speciﬁc SF1 knockout mice are sterile and never mature
sexually. Consistent with a direct role of SF1 at the pituitary level,
FSH and LH are markedly decreased in the pituitary-speciﬁc SF1
knockout mice as well as are gonadotropin β-subunit and Gnrhr
mRNAs as assessed by semi-quantitative RT-PCR.
The important role of SF1 has been further conﬁrmed in
humans by the discovery of a heterozygous missense mutation
in the DNA binding domain of SF1 in a patient with complete
sex reversal, testicular dysgenesis, and adrenal failure (Achermann
et al., 1999). However, this patient displayed a relative preservation
of gonadotrope function. This may be due either to its heterozy-
gous genotype or to a relative autonomy of the gonadotrope
function with respect to SF1. In agreement with the latest hypoth-
esis, GnRH treatment can restore LH and FSH secretion in SF1
knockout mice (Ikeda et al., 1995), suggesting that SF1 is not
required for the emergence andmaintenance of gonadotrope func-
tion. Furthermore, some tissues known to express GnRHR such
as amygdala and hippocampus are deprived of SF1 (Schang et al.,
2011b). This suggests that other factor(s) than SF1 are needed for
the tissue-speciﬁc transcriptional onset of the Gnrhr. To identify
this (or these) factor(s), several parameters must be considered.
From an ontogenetic point of view, the date of appearance of
the Gnrhr transcripts must be correlated with the presence of the
factor in the fetal pituitary or in fetal tissues that will express
the GnRHR in the adult. For instance, binding sites for GnRH
have been detected as early as 12–13 days of gestation in the rat
developing pituitary and GnRHR mRNA at 14.5 and 15.5 days
post-conception in testis and ovary from rat fetuses (Aubert et al.,
1985; Jennes, 1990; Botté et al., 1998). This factor should also be
able to activate the promoter of the Gnrhr in an SF1-independent
manner in transient transfection assays.
CONCLUSIONS AND PERSPECTIVES
An increasingnumber of studies on gene regulations andpromoter
activities aim to demonstrate the existence of speciﬁc regulatory
units that bring together several response elements. From one
tissue to another, the same elements may bind different factors
resulting in tissue- or cell-speciﬁc modulations of gene expression.
This ability to bind different factors is likely facilitated by sequence
degeneracy of the response elements that lie within these reg-
ulatory units. Consequently, the degenerated response elements
may be less efﬁcient than their canonical counterparts when they
are isolated from their promoter context. Efﬁciency is recovered
in the original promoter context through synergistic interactions
with other transcription factors belonging to the regulatory unit.
Interestingly, this synergy may be attenuated if the wild-type
degenerated element is artiﬁcially replaced by its canonical coun-
terpart (Ito et al., 2000). In the Gnrhr promoters, several elements
display such characteristics. In particular, the SF1 binding site and
the proximal CRE in the rat and mouse promoter differ from the
consensus sequence (TGACGTTT instead of TGACGTCA for the
later). In gel-shift experiment, both the SF1 element and the CRE
display an apparent weaker afﬁnity for their cognate transcription
factors than the SF1 binding site from the rat aromatase gene or
the canonical CRE sequence (Pincas et al., 2001a,b). PACAP- and
PKA-dependent regulations of the rat promoter are mediated by
these two elements that may thus be considered as a cAMP reg-
ulatory unit (Roesler, 2000). The SURG-1 and SURG-2 elements
establish another functional regulatory unit since they are both
required for the GnRH up-regulation of the mouse promoter.
The distal GnSE together with the proximal domain containing
the SF1 binding site also form a regulatory unit for the tissue-
speciﬁc activity of the rat promoter. Different regulatory units
may also bind different combinations of factors depending on
the tissue or the cell type that expresses the Gnrhr. We have
recently demonstrated that OTX2 interacted with two distinct
partners depending on the cell context (Schang et al., 2012a).
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In a gonadotrope cell context, OTX2 interacted with PROP1
on two adjacent response elements located between −388 and
−357, each of them encompassing a core TAAT motif. In a neu-
tral cell context, OTX2 acted in synergy with CREB and formed
a regulatory unit that involved CRE, an AP1 response element
together with a new OTX2 binding site containing a TAAT core
motif located at −163/−160. This motif is thus located 50 bp
upstream of the CRE and 180 bp downstream of the AP1 ele-
ment establishing a regulatory unit extending over 200 bp within
the proximal promoter, markedly larger than the PROP1/OTX2
regulatory unit (Schang et al., 2012a). Whether such difference in
size of these regulatory units as well as the other cited above is
functionally relevant remains to be determined. In this respect,
an important point that must be considered is the chromatin
structure that depends on epigenetic modiﬁcations. At least,
two histone H3 modiﬁcations are predominantly involved in
transcriptional regulation: tri-methylation of Lys 4 of histone
H3 (H3K4me3) and tri-methylation of Lys 27 of histone H3
(H3K27me3; see review in Greer and Shi, 2012). They are linked
to gene activity and gene silencing, respectively. H3K4me3 is cat-
alyzed by trithorax group (trxG) proteins, whereas H3K27me3
is catalyzed by polycomb-group (PcG) proteins (Schuettengru-
ber et al., 2007; Ku et al., 2008). PcG proteins reside in two
main complexes, termed Polycomb repressive complexes 1 and
2 (PRC1 and PRC2). PRC2 catalyzes H3K27me3 and compo-
nents of PRC1 are recruited to the modiﬁed histone leading
to ubiquitinylation of histone H2A at lysine 119 which in turn
prohibits RNA polymerase II elongation (Simon and Kingston,
2009). This results in stable transcriptional repression. Analysis of
H3K4me3 and H3K27me3 modiﬁcations by ChIP assay showed
that in gonadotrope cell lines, the Gnrhr promoter preferentially
displayed the active mark whereas in lactosomatotrope or corti-
cotrope cell lines, it displayed preferentially the repressive mark
(unpublished data). This is well correlated with Gnrhr mRNA lev-
els that are not detected in lactosomatotrope and corticotrope
cell lines. Constitutive Gnrhr transcription is thus likely con-
trolled by mechanisms involving trxG proteins in gonadotrope
cells whereas in other pituitary cells, PcG proteins stably repress
Gnrhr expression. In mammals, composition of trxG and PcG
protein complexes displays broad diversity depending on the con-
sidered family of genes. A critical point would be to determine
what are the main actors involved in histone methyltransferase
and demethylase activity regarding the Gnrhr. Furthermore, PcG
complexes are known to be clustered into subnuclear structures
that look like nuclear foci termed polycomb bodies (Pirrotta
and Li, 2012). Conversely, active genes are preferentially located
in different subnuclear structures referred to as transcription
factories that contain active RNA polymerase II or interchro-
matin granule clusters (also termed nuclear speckles) that contain
histone-modifying enzymes, transcription elongation factors, and
splicing machinery (Meldi and Brickner, 2011; Spector and Lam-
ond, 2011). In the developing pituitary gland, lineage speciﬁcation
likely requires relocation of marker genes like the Gnrhr into
these subnuclear structures (Yang et al., 2011). The elucidation
of the mechanisms underlying this reorganization would permit
to shed new light on Gnrhr expression, on gonadotrope cell lin-
eage speciﬁcation anddifferentiation, andmore generally onorgan
development.
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